Results 51 to 60 of about 145,724 (263)

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Microvascular Damage Is Associated With Carotid Wall Structural Changes in Systemic Sclerosis: A Capillaroscopy and Ultrasound‐Based Observational Study

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by cardiovascular risk excess not fully explained by traditional factors. Whether the severity of microvascular damage correlates with structural subclinical atherosclerosis remains unclear. We investigated the relationship between nailfold videocapillaroscopy (NVC) abnormalities and carotid ...
Eugenio Capparelli, Luca Clerici, Francesco Lapia, Giusy C. Moltisanti, Eleonora Zaccara, Greta Pellegrino, Daniela Bompane, Francesca Capelli, Letizia Ferrami, Laura Castelnovo, Antonio Tamburello, Maria Sole Chimenti, Paola Faggioli, Antonino Mazzone   +13 more
wiley   +1 more source

Topically Delivered Treg‐Attracting Microparticle‐Hydrogel Composites Recruit Regulatory T Cells and Limit Cardiac Injury After Severe Ischemia

Advanced Healthcare Materials, EarlyView.
CCL22‐releasing PLGA microparticles (MP) suspended in topically applied hydrogels (HEART) establish a sustained chemokine gradient at the injured myocardium. HEART recruits CCR4+ regulatory T cells, reduces infarct size and graft fibrosis, and improves cardiac function.
Matthew A. Borrelli, Alexis T. Reese, Jordan J. P. Warunek, Betsy Ann Varghese, Canxing Lin, Jeffery J. Baust, Brenda McMahon, Steven R. Little, Hēth R. Turnquist   +8 more
wiley   +1 more source

Recent Advances in Transparent Microelectrode Device Architecture and Fabrication Strategies for Biomedical Applications

Advanced Materials Technologies, EarlyView.
Transparent microelectrode arrays enable simultaneous optical and electrical electrophysiology with high spatiotemporal resolution, allowing multimodal observations of dynamic biological systems. Advances in materials and device architectures improve device performance by addressing key trade‐offs between optical transparency, impedance, and ...
Michael Abraham Listyawan, Tran Bach Dang, Chi Cong Nguyen, Yee Lap Pong, Tianruo Guo, Thanh Nho Do, Hoang‐Phuong Phan   +6 more
wiley   +1 more source

Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis

Acta Pharmaceutica Sinica B
Myocardial fibrosis is a serious cause of heart failure and even sudden cardiac death. However, the mechanisms underlying myocardial ischemia-induced cardiac fibrosis remain unclear.
Xuewen Yang, Yanwei Zhang, Xiaoping Leng, Yanying Wang, Manyu Gong, Dongping Liu, Haodong Li, Zhiyuan Du, Zhuo Wang, Lina Xuan, Ting Zhang, Han Sun, Xiyang Zhang, Jie Liu, Tong Liu, Tiantian Gong, Zhengyang Li, Shengqi Liang, Lihua Sun, Lei Jiao, Baofeng Yang, Ying Zhang   +21 more
doaj   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

EZH2 mitigates the cardioprotective effects of mesenchymal stem cell-secreted exosomes against infarction via HMGA2-mediated PI3K/AKT signaling

BMC Cardiovascular Disorders, 2022
Background Mesenchymal stem cell-derived exosomes (MSC-EXO) have emerged as novel therapeutic strategies for myocardial infarction (MI). However, many questions remain untouched and unanswered regarding their roles in myocardial fibrosis.
Wei Jiao, Jie Hao, Yanan Xie, Mingjie Meng, Weinian Gao   +4 more
doaj   +1 more source

Programmable Paracrine‐Mimetic Microneedle System for Temporal Regulation of Cardiac Repair

Advanced Science, EarlyView.
Temporal signaling is encoded into a programmable paracrine‐mimetic microneedle patch via tris(2,2'‐bipyridyl)dichlororuthenium(II) hexahydrate/sodium persulfate‐tuned hydrogel microparticles that deliver TGF‐β, IGF‐1, and VEGF over phase‐matched 7‐, 14‐, and 28‐day windows.
Yichen Dai, Pengchong Du, Zhaoyang Wang, Surilige, Rangga Fokta, Renjian Tan, Xiqing Zhao, Shuoyi Zhang, Yuecheng Wang, Yixin Zhang, Ziliang Fu, Rui Gong, Cheng Jiang, Yisheng He, Qiguang Wang, Renke Li, Khoon Lim, Junnan Tang, Xiaolin Cui   +18 more
wiley   +1 more source

Chinese and western medicine treatment of myocardial fibrosis drugs

Frontiers in Cardiovascular Medicine
Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases, such as myocardial infarction, myocardial ischemia, and sudden cardiac death.
Yuxi Zhu, Yuxi Zhu, Fangmei Zhang, Zhongcheng Li, Yu Zhou, Yi Shu, Jian Ruan, Guo Chen   +7 more
doaj   +1 more source

Myocardial fibrosis during atrial fibrillation: histological and cardiographic predictors

Известия высших учебных заведений. Поволжский регион: Медицинские науки, 2023
Background. The formation of myocardial fibrosis is the leading mechanism for occurrence of atrial fibrillation (AF). In this regard, an attempt to prevent development of myocardial fibrosis and its treatment is pathogenetically expedient.
R.F. Rakhmatullov, F.K. Rakhmatullov, N.A. Timofeeva   +2 more
doaj   +1 more source